Cargando…

Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo‐Controlled Trial

BACKGROUND: The sodium/glucose cotransporter 2 inhibitor empagliflozin has cardiorenal protective properties through mechanisms beyond glucose control. In this study we assessed whether empagliflozin modifies renal oxygenation as a possible mechanism of renal protection, and determined the metabolic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zanchi, Anne, Burnier, Michel, Muller, Marie‐Eve, Ghajarzadeh‐Wurzner, Arlène, Maillard, Marc, Loncle, Nicolas, Milani, Bastien, Dufour, Nathalie, Bonny, Olivier, Pruijm, Menno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670540/ https://www.ncbi.nlm.nih.gov/pubmed/32567439 http://dx.doi.org/10.1161/JAHA.119.016173

Ejemplares similares

Twenty-Four Hour Blood Pressure Response to Empagliflozin and Its Determinants in Normotensive Non-diabetic Subjects
por: Zanchi, Anne, et al.
Publicado: (2022)

Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol
por: Muller, Marie-Eve, et al.
Publicado: (2018)

Blood Oxygenation Level-Dependent MRI to Assess Renal Oxygenation in Renal Diseases: Progresses and Challenges
por: Pruijm, Menno, et al.
Publicado: (2017)

Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine
por: Pruijm, Menno T, et al.
Publicado: (2008)

Blood pressure and vascular determinants of glomerular filtration rate decline in diabetic kidney disease
por: Truscello, Luca, et al.
Publicado: (2023)

Long-term use and tolerability of irbesartan for control of hypertension
por: Forni, Valentina, et al.
Publicado: (2011)

Impact of the severity of obesity on microalbuminuria in obese normotensive nondiabetic individuals
por: Minoo, Farzanehsadat, et al.
Publicado: (2015)

Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats
por: Kim, Sua, et al.
Publicado: (2019)

Interprofessional Medication Adherence Program for Patients With Diabetic Kidney Disease: Protocol for a Randomized Controlled and Qualitative Study (PANDIA-IRIS)
por: Bandiera, Carole, et al.
Publicado: (2021)

The Relative Effects of Obesity and Insulin Resistance on Cardiovascular Risk Factors in Nondiabetic and Normotensive Men
por: Park, Seung Ha, et al.
Publicado: (2004)

Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
por: Dziadkowiec, Karolina N., et al.
Publicado: (2021)

Clinical Benefits of an Adherence Monitoring Program in the Management of Secondary Hyperparathyroidism with Cinacalcet: Results of a Prospective Randomized Controlled Study
por: Forni Ogna, Valentina, et al.
Publicado: (2013)

Comparison of left ventricular mass in normotensive type 2 diabetes mellitus patients with that in the nondiabetic population
por: Santra, Sukamal, et al.
Publicado: (2011)

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
por: Matthews, Jennifer, et al.
Publicado: (2022)

SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
por: Lim, Ven G., et al.
Publicado: (2019)

The Rationale and Evidence for SGLT2 Inhibitors as a Treatment for Nondiabetic Glomerular Disease
por: Miyata, Kana N., et al.
Publicado: (2021)

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
por: Aroor, Annayya R., et al.
Publicado: (2018)

Renal Tissue Oxygenation in Essential Hypertension and Chronic Kidney Disease
por: Pruijm, Menno, et al.
Publicado: (2013)

Functional magnetic resonance imaging of the kidneys: where do we stand? The perspective of the European COST Action PARENCHIMA
por: Caroli, Anna, et al.
Publicado: (2018)

Letter Regarding “Granulomatous Inflammation and Hypercalcemia in Patients With Severe Systemic Oxalosis”
por: Halfon, Matthieu, et al.
Publicado: (2022)

Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients
por: Genton, Laurence, et al.
Publicado: (2021)

Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle
por: Anker, Stefan D., et al.
Publicado: (2018)

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
por: Steven, Sebastian, et al.
Publicado: (2017)

Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More?
por: Mantsounga, Chris Sorel, et al.
Publicado: (2019)

SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart
por: Karpushev, Alexey V., et al.
Publicado: (2022)

Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
por: Heimke, Marvin, et al.
Publicado: (2022)

Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction
por: Connelly, Kim A., et al.
Publicado: (2019)

Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats
por: Ala, Moein, et al.
Publicado: (2022)

The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial
por: Kolwelter, Julie, et al.
Publicado: (2022)

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling
por: Verma, Raj, et al.
Publicado: (2023)

Validation of the optical Aktiia bracelet in different body positions for the persistent monitoring of blood pressure
por: Sola, Josep, et al.
Publicado: (2021)

Blood pressure from the optical Aktiia Bracelet: a 1-month validation study using an extended ISO81060-2 protocol adapted for a cuffless wrist device
por: Vybornova, Anna, et al.
Publicado: (2021)

Glycine increases fat‐free mass in malnourished haemodialysis patients: a randomized double‐blind crossover trial
por: Genton, Laurence, et al.
Publicado: (2021)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
por: Li, Chenguang, et al.
Publicado: (2019)

Correction to: Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Publicado: (2022)

Determinants of Renal Tissue Oxygenation as Measured with BOLD-MRI in Chronic Kidney Disease and Hypertension in Humans
por: Pruijm, Menno, et al.
Publicado: (2014)

Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass
por: Ferreira, Antonio, et al.
Publicado: (2022)

Smartphone based blood pressure measurement: accuracy of the OptiBP mobile application according to the AAMI/ESH/ISO universal validation protocol
por: Degott, Jean, et al.
Publicado: (2021)

Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial
por: Schietzel, Simeon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5s3fji1onnbmrt90vtov133edr